Clinical Aspects of the Nervous System

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 368-381

  West, Sterling G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920949304     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00029-7     Document Type: Chapter

References (75)

1. West S The nervous system. Dubois' Lupus Erythematosus 2007, 707-746. Lippincott-Williams & Wilkins, Philadelphia. ed 7. D.J. Wallace, B.H. Hahn (Eds.).
2. Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008, 721-729.
3. Cervera R, Khamashta MA, Font J, et al: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients 82:299-308, 2003.
4. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
5. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes. Arthritis Rheum 1999, 42:599-608.
6. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Care & Res 2001, 45:419-423.
7. Hanly JG ACR Classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004, 13:861-864.
8. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
9. Johnson RT, Richardson EP The neurological manifestations of systemic lupus erythematosus. A clinical-pathological study of 24 cases and review of the literature. Medicine 1968, 47:337-369.
10. Ellis SG, Verity MA Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979, 8:212-221.
11. Devinsky O, Petito CK, Alonso DR Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988, 23:380-384.
12. Belmont HM, Abramson S, Lie JT Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996, 39:9-22.
13. Davey R, Bamford J, Emery P The role of endothelial dysfunction in the pathogenesis of neuropsychiatric systemic lupus erythematosus. Lupus 2010, 19:797-802.
14. Abbott NJ, Mendonca LLF, Dolman DEM The blood-brain barrier in systemic lupus erythematosus. Lupus 2003, 12:908-915.
15. West SG, Emlen W, Wener MH, et al. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995, 99:153-163.
16. Kozora E, Ellison MC, West S Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004, 51:810-818.
17. Carbotte RM, Denburg SD, Denburg JA Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986, 174:357-364.
18. Denburg SD, Denburg JA Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003, 12:883-890.
19. Hanly JG, Cassell K, Fisk JD Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 1997, 40:1542-1543.
20. Kozora E Neuropsychological functioning in systemic lupus erythematosus. Textbook of Clinical Neuropsychology 2008, 636-649. Taylor and Francis, New York. J.E. Morgan, J.H. Ricker (Eds.).
21. Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A 2010, 107:18569-18574.
22. Gómez-Puerta JA, Cervera R, Calvo LM, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology 2005, 44:95-99.
23. Brunner HI, Ruth NM, German A, et al. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum 2007, 57:1174-1182.
24. Mitsikostas DD, Sfikakis PP, Goadsby PJ A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004, 127:1200-1209.
25. Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, et al. Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. Lupus 1999, 8:151-156.
26. Green L, Vinker S, Amital H, et al. Pseudotumor cerebri in systemic lupus erythematosus. Seminars Arthritis Rheum 1995, 25:103-108.
27. Futrell N, Millikan C Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989, 20:583-591.
28. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005, 52:2774-2782.
29. Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007, 38:281-285.
30. Krishnan E Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 2005, 118:1415.e1-1415.e7.
31. Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology 2007, 108:331-337.
32. Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000, 59:120-124.
33. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non-organ specific autoimmunity. Arch Neurol 2008, 65:78-83.
34. Kolfenbach JR, Horner BJ, Ferucci ED, et al. Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res 2011, 63:1203-1208.
35. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997, 76:203-212.
36. Ferreira S, D'Cruz DP, Hughes GR Multiple sclerosis, neuropsychiatric lupus, and antiphospholipid syndrome: where do we stand?. Rheumatology 2005, 44:434-442.
37. Appenzeller S, Cendes F, Costallat LTL Epileptic seizures in systemic lupus erythematosus. Neurology 2004, 63:1808-1812.
38. Cimaz R, Meroni PL, Schoenfeld Y Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006, 15:191-197.
39. Caronti B, Calderaro C, Alessandri C, et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmunity 1998, 11:425-429.
40. Pego-Reigosa JM, Isenberg DA Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology 2008, 47:1498-1502.
41. Briani C, Lucchetta M, Ghirardello A, et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmunity 2009, 32:79-84.
42. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006, 54:312-324.
43. Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007, 6:421-426.
44. Omdal R, Loseth S, Torbergsen T, et al. Peripheral neuropathy in systemic lupus erythematosusa longitudinal study. Acta Neurol Scand 2001, 103:386-391.
45. Goransson LG, Tjensvoll AB, Herigstad A, et al. Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol 2006, 63:401-404.
46. Shalimar, Handa R, Deepak KK, et al. Autonomic dysfunction in systemic lupus erythematosus. Rheumatol Int 2006, 26:837-840.
47. Omar HA, Alzahrani MA, Al Bshabshe AAA, et al. Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature. Clin Exp Nephrol 2010, 14:272-276.
48. Muscal E, Brey RL Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clinics 2010, 28:61-73.
49. Yancey CL, Doughty RA, Athreya BH Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981, 24:1389-1395.
50. Sibbitt WL, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002, 29:1536-1542.
51. Boddaert J, Huong DLT, Wechsler B, et al. Late-onset systemic lupus erythematosus. Medicine 2004, 83:348-359.
52. Mak A, Chan BPL, Yeh IB, et al. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology 2008, 47:256-262.
53. Zandman-Goddard G, Chapman J, Shoenfeld Y Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007, 36:297-315.
54. Kimura A, Kanoh Y, Sakurai T, et al. Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 2010, 74:1372-1379.
55. Hanley JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008, 58:843-853.
56. Love PE, Santora SA Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Int Med 1990, 112:682-698.
57. Levine SR, Brey RL, Joseph CLM, et al. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992, 23(Supp I):I29-I32.
58. Connor P, Hunt BJ Cerebral haemostasis and antiphospholipid antibodies. Lupus 2003, 12:929-934.
59. Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006, 13:77-83.
60. Ghirardello A, Briani C, Lucchetta M, et al. Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies. Lupus 2010, 19:771-773.
61. Matus S, Burgos PV, Bravo-Zehnder M, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007, 204:3221-3234.
62. Kang EH, Shen GQ, Morris R, et al. Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases. Lupus 2008, 17:21-25.
63. Hirohata S, Taketani T A serial study of changes in intrathecal immunoglobulin synthesis in a patient with central nervous system systemic lupus erythematosus. J Rheumatol 1987, 14:1055-1057.
64. Okamoto H, Kobayashi A, Yamanaka H: Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomedicine Biotechnol; doi: 10.1155/2010/268436.
65. Sibbitt WL, Sibbitt RR, Brooks WM Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999, 42:2026-2038.
66. Appenzeller S, Pike GB, Clarke AE Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008, 34:361-366.
67. Sanna G, Bertolaccini ML, Khamashta MA Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Current Pharma Design 2008, 14:1261-1269.
68. Trevsani VF, Castro AA, Neves Neto JF, et al. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2000, CD002265.
69. Braile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:620-625.
70. Ruiz-Irastorza G, Hunt BJ, Khamashta MA A systemic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57:1487-1495.
71. Cohen H, Machin SJ Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?. Lupus 2010, 19:486-491.
72. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
73. Jonsen A, Bengtsson AA, Nived O, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology 2002, 41:1308-1312.
74. Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009, 36:1449-1459.
75. Karassa FP, Ioannidis JP, Boki JA, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 2000, 109:628-634.